ATE423559T1 - Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren - Google Patents

Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren

Info

Publication number
ATE423559T1
ATE423559T1 AT02717766T AT02717766T ATE423559T1 AT E423559 T1 ATE423559 T1 AT E423559T1 AT 02717766 T AT02717766 T AT 02717766T AT 02717766 T AT02717766 T AT 02717766T AT E423559 T1 ATE423559 T1 AT E423559T1
Authority
AT
Austria
Prior art keywords
combination therapy
ppar modulators
absorption inhibitors
glucose absorption
ppar
Prior art date
Application number
AT02717766T
Other languages
English (en)
Inventor
Jacqueline Bussolari
Xiaoli Chen
Bruce Conway
Keith Demarest
Hamish Ross
Rafael Severino
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Application granted granted Critical
Publication of ATE423559T1 publication Critical patent/ATE423559T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT02717766T 2001-04-04 2002-04-03 Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren ATE423559T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28142901P 2001-04-04 2001-04-04

Publications (1)

Publication Number Publication Date
ATE423559T1 true ATE423559T1 (de) 2009-03-15

Family

ID=23077253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02717766T ATE423559T1 (de) 2001-04-04 2002-04-03 Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren

Country Status (11)

Country Link
US (3) US20030045553A1 (de)
EP (2) EP2065044A1 (de)
JP (1) JP4590159B2 (de)
CN (1) CN100577175C (de)
AT (1) ATE423559T1 (de)
CA (1) CA2442917C (de)
DE (1) DE60231295D1 (de)
ES (1) ES2321815T3 (de)
MY (1) MY180762A (de)
TW (1) TWI330084B (de)
WO (1) WO2002080936A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
WO2002080935A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
US20090162342A1 (en) * 2001-06-07 2009-06-25 Sanomune Inc. Therapeutic uses of glandular kallikrein
EP1388352A1 (de) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2004108126A1 (en) * 2003-06-06 2004-12-16 Snowden Pharmaceuticals, Llc Fibric acid derivatives for the treatment of irritable bowel syndrome
AU2004250994B2 (en) * 2003-06-27 2010-12-02 Dr. Reddy's Research Foundation Compositions comprising balaglitazone and further antidiabetic compounds
KR20060121887A (ko) * 2003-09-23 2006-11-29 디에스엠 아이피 어셋츠 비.브이. 진성 당뇨병의 치료 및 예방용 조성물
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
WO2005070413A1 (ja) * 2004-01-23 2005-08-04 Japan Science And Technology Agency レチノイン酸を含有する糖尿病治療薬
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
NZ550340A (en) 2004-03-17 2010-08-27 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle using a retinoid
JP5010918B2 (ja) * 2004-07-21 2012-08-29 キッセイ薬品工業株式会社 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
US7767682B2 (en) * 2005-03-03 2010-08-03 Glaxosmithkline Llc Medicaments
EP1931805A2 (de) * 2005-09-30 2008-06-18 Perlegen Sciences, Inc. Verfahren und zusammensetzungen zum screening und zur behandlung von störungen der blut-glucose-regulation
EP1785133A1 (de) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
US8666671B2 (en) * 2007-07-05 2014-03-04 Enhanced Pharmaceuticals, Inc. Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
EP2236137B1 (de) * 2008-01-31 2015-06-24 Astellas Pharma Inc. Pharmazeutische zusammensetzung zur behandlung von fettlebererkrankungen
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
AP2728A (en) * 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
MY182720A (en) 2009-04-16 2021-02-03 Taisho Pharmaceutical Co Ltd Pharmaceutical compositions
JP5902619B2 (ja) * 2009-07-10 2016-04-13 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｘｒアゴニスト化合物および方法
WO2011039338A2 (en) 2009-10-02 2011-04-07 Sanofi-Aventis Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2667854T3 (es) * 2011-07-07 2018-05-14 Holy Stone Healthcare Co., Ltd. Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación
US9451987B2 (en) 2011-11-16 2016-09-27 K2M, Inc. System and method for spinal correction
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (de) 2012-06-04 2017-02-22 Diamedica Inc. Kallikrein-1-glycosylierungsisoformen aus menschlichem gewebe
CN102727477B (zh) * 2012-06-14 2014-07-16 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治糖尿病药物中的应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
US20210059997A1 (en) * 2017-12-28 2021-03-04 University Of Fukui Prophylactic agent and/or therapeutic agent for cataract, medicinal composition for preventing and/or treating cataract, use of ppar activator for producing same, and eyedrops
CN111437393B (zh) * 2020-04-30 2021-03-02 深圳微芯生物科技股份有限公司 用于糖尿病及其并发症治疗的联合用药及其药物组合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0842925A1 (de) * 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
JPH0253573A (ja) * 1988-08-11 1990-02-22 Nippon Riki Kk ラチェットレンチの製造法
US5731299A (en) 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
JP2762903B2 (ja) 1992-11-12 1998-06-11 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
JP2795162B2 (ja) 1993-02-18 1998-09-10 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
JP2906978B2 (ja) 1993-02-25 1999-06-21 田辺製薬株式会社 血糖降下剤
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
ES2216062T3 (es) 1995-09-18 2004-10-16 Ligand Pharmaceuticals, Inc. Tratamiento de la niddm con agonistas del rxr.
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
PL331148A1 (en) 1996-07-12 1999-06-21 Smithkline Beecham Plc Novel method of treating the leptin immunity
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
ES2176600T3 (es) * 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JP4100734B2 (ja) 1997-04-30 2008-06-11 Ｓａｂｉｃイノベーティブプラスチックスジャパン合同会社 熱可塑性樹脂組成物
CA2294134A1 (en) 1997-06-18 1998-12-23 Stephen Alistair Smith Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
AU1185100A (en) * 1998-11-20 2000-06-13 Mitsubishi Chemical Corporation Crystals of 5-((6-(2-fluorobenzyl)oxy-2-naphthyl)methyl)- 2,4-thiazolidinedione
US6337426B1 (en) 1998-11-23 2002-01-08 Nalco/Exxon Energy Chemicals, L.P. Antifoulant compositions and processes
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
WO2000065052A1 (en) 1999-04-22 2000-11-02 Habener Joel F Bridge-1, a transcription factor
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2383347A1 (en) 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
BRPI0013667B8 (pt) 1999-08-31 2021-05-25 Kissei Pharmaceutical derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos e seus intermediários na produção deles
PE20010580A1 (es) 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP2001192375A (ja) * 1999-10-29 2001-07-17 Takeda Chem Ind Ltd オキシイミノアルカン酸誘導体の結晶
TW558554B (en) 1999-10-29 2003-10-21 Takeda Chemical Industries Ltd Crystals of oxyiminoalkanoic acid derivative
PL356487A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
ATE334718T1 (de) 2000-10-30 2006-08-15 Ortho Mcneil Pharm Inc Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
MXPA03005923A (es) 2000-12-28 2004-01-26 Kissei Pharmaceuticals Co Ltd Derivados de glupopiranosiloxipirazol y su uso en medicinas.
WO2002080935A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators

Also Published As

Publication number Publication date
US20080096802A1 (en) 2008-04-24
CN1568190A (zh) 2005-01-19
EP1381361A1 (de) 2004-01-21
EP2065044A1 (de) 2009-06-03
US8278268B2 (en) 2012-10-02
WO2002080936A1 (en) 2002-10-17
MY180762A (en) 2020-12-08
CN100577175C (zh) 2010-01-06
JP2004529915A (ja) 2004-09-30
EP1381361B1 (de) 2009-02-25
TWI330084B (en) 2010-09-11
CA2442917C (en) 2011-02-01
US20030045553A1 (en) 2003-03-06
JP4590159B2 (ja) 2010-12-01
DE60231295D1 (de) 2009-04-09
CA2442917A1 (en) 2002-10-17
US20030199557A1 (en) 2003-10-23
ES2321815T3 (es) 2009-06-12

Similar Documents

Publication Publication Date Title
ATE423559T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
ATE442148T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
PT1333887E (pt) Metodo de tratamento de desordens musculares
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
IL194950A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
DE60035232D1 (de) (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom
NO20053041D0 (no) Behandling av diabetes.
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
NO20045554L (no) Fremgangsmate for behandling av diabetes
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
NO20051847L (no) Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.
NO20051521L (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
FI20011298L (fi) Puunkäsittelyliuos ja menetelmä puun säilyvyyden parantamiseksi
SE0103276D0 (sv) Anordning för administrering av salva till en hudyta
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
AU2003221350A1 (en) Light amplifying device and method of manufacturing the device, light source device using the light amplifying device, light treatment device using the light source device, and exposure device using the light source device
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
DK1366033T3 (da) Kemiske forbindelser
DK0673902T3 (da) Middel til behandling af bioaffald

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties